Status:
ACTIVE_NOT_RECRUITING
A Neurofeedback Booster for Emotion Regulation Therapy
Lead Sponsor:
Christian Paret
Collaborating Sponsors:
Yale University
AE Foundation
Conditions:
Borderline Personality Disorder
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
This is a proof-of-concept study that aims to test the additional value of adjuvant neurofeedback treatment for psychotherapy. Three sessions of real-time fMRI neurofeedback will be administered to N=...
Eligibility Criteria
Inclusion
- DSM-5 BPD diagnosis
- informed consent
- EtOH and tox negative on the day of neurofeedback
- BSL-23 score \>=1.87 at DBT halftime
Exclusion
- pharmacotherapy with opiates
- standing benzodiazepines (bedtime-only benzodiazepines and anti-histamines allowed)
- pregnancy
- epilepsy
- life-time diagnosis schizophrenia or bipolar disorder I
- significant current or past neurological illness
- BMI\<16.5
- usual safety criteria for magnetic resonance imaging
Key Trial Info
Start Date :
July 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT04333888
Start Date
July 21 2020
End Date
December 1 2025
Last Update
March 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Institute of Mental Health
Mannheim, Germany, 68159